Although tumor necrosis factor alpha (TNF-a) is known to play a critical role in intervertebral disc (IVD) degeneration, the effect of TNF-a on nucleus pulposus (NP) cells has not yet been elucidated. The aim of this study was to explore the effect of TNF-a on proliferation of human NP cells. NP cells were treated with different concentrations of TNF-a. Cell proliferation was determined by cell counting kit-8 (CCK-8) analysis and Ki67 immunofluorescence staining, and expression of cyclin B1 was studied by quantitative real-time RT-PCR. Cell cycle was measured by flow cytometry and cell apoptosis was analyzed using an Annexin V-fluorescein isothiocyanate (FITC) & propidium iodide (PI) apoptosis detection kit. To identify the mechanism by which TNF-a induced proliferation of NP cells, selective inhibitors of major signaling pathways were used and Western blotting was carried out. Treatment with TNF-a increased cell viability (as determined by CCK-8 analysis) and expression of cyclin B1 and the number of Ki67-positive and S-phase NP cells, indicating enhancement of proliferation. Consistent with this, NP cell apoptosis was suppressed by TNF-a treatment. Moreover, inhibition of NF-kB, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) blocked TNF-a-stimulated proliferation of NP cells. In conclusion, the current findings suggest that the effect of TNF-a on IVD degeneration involves promotion of the proliferation of human NP cells via the NF-kB, JNK, and p38 MAPK pathways.
Introduction
Although intervertebral disc (IVD) degeneration has been characterized as a chronic process involving multiple factors, its exact mechanism has not been fully elucidated. Previous studies have demonstrated the presence in the degenerative disc of a number of inflammatory cytokines, including tumor necrosis factor alpha (TNF-a), 1-3 interleukin-1a (IL-1a), 1 interleukin-1b (IL-1b), 1, 4 interleukin-6 (IL-6), 1, 5 granulocyte macrophage colony stimulation factor (GM-CSF), 1, 5 transforming growth factor-b1 (TGF-b1), 6, 7 insulin-like growth factor-1 (IGF-1), 7 and prostaglandin E2 (PGE2), 8 suggesting that inflammation plays an important role in IVD degeneration.
TNF-a, a member of the TNF superfamily, is a potent proinflammatory cytokine that is expressed at high levels in resident nucleus pulposus (NP) and annulus fibrosus (AF) cells during IVD degeneration and herniation. 3, 9 TNF-a plays important roles in the pathophysiology of IVD degeneration, including increasing levels of other potent cytokines, such as IL-1, IL-6, IL-8, and PGE2, and promoting the development of inflammatory hyperalgesia. 3 Since TNF-a stimulates expression of ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin motifs 4), ADAMTS5, and matrix metalloproteinases (MMPs), and inhibits synthesis of collagen and proteoglycan, [10] [11] [12] [13] cells were treated with TNF-a to model degenerative changes in IVD. 11, 14 Indeed, treatment with TNF-a for seven days has been shown to induce senescence of disc cells in a bovine organ culture model. 10 Although it is reasonable to speculate that TNF-a causes degenerative changes in IVD, the question of whether it initially promotes proliferation of human NP cells is unclear.
TNF-a has been shown to promote cell proliferation, 15 a common event in the initiation and promotion of malignant disease. 16, 17 For example, TNF-a stimulates tumor growth and metastasis in a mouse model of pancreatic cancer, an effect that was reversed by treatment with the TNF-a inhibitors infliximab or etanercept. 18 Moreover, TNF-a enhances the proliferation of vascular smooth muscle cells in atherosclerosis, 19, 20 and promotes the growth of skin, ovarian, and intestinal tumors. [21] [22] [23] It has been reported that disc cell density increases with age or during degeneration. [24] [25] [26] [27] A characteristic feature of IVD degeneration is the appearance in degenerative areas of cell clusters, 24 conceivably arising from proliferation of disc cells in response to inflammatory damage to the degenerative disc. 28 While TNF-a potentially plays a role in the proliferation of cells in the NP, the inner core of the IVD, this has not been studied to date. Accordingly, the purpose of the present study was to assess whether TNF-a promotes the proliferation of human NP cells.
Materials and methods

Cells and reagents
Human NP cells, NP cell medium, and trypsin/ethylenediaminetetraacetic acid (trypsin/EDTA) solution were purchased from Sciencell Research Laboratories (Carlsbad, CA). Human NP cells were isolated from human IVD and characterized by immunofluorescence analysis using antibodies against fibronectin and vimentin by the manufacturer. Recombinant human TNF-a was obtained from Peprotech (Rocky Hill, NJ). The cell counting kit-8 (CCK-8) was purchased from Dojindo (Tokyo, Japan). Rabbit antihuman Ki67 polyclonal antibody was purchased from Abcam (Cambridge, UK). Alexa Fluor 594 donkey antirabbit IgG antibody was obtained from Molecular Probes (Carlsbad, CA). The Annexin V-fluorescein isothiocyanate (FITC) & propidium iodide (PI) apoptosis detection kit was purchased from Jiamay Biotech (Beijing, China), and PI/RNase Staining Buffer was purchased from BD Biosciences (San Diego, CA). Antibodies against phospho-p65 (p-p65), p65, p-p38, p38, p-c-Jun N-terminal kinase (JNK), JNK, and horseradish peroxidase (HRP)-linked anti-rabbit IgG antibody and U0126 were obtained from Cell Signaling Technology (Danvers, MA). SP60025, SB203580, and pyrrolidinedithiocarbamate ammonium were obtained from Tocris (Bristol, UK).
Cell culture and TNF-a treatment
NP cells were cultured with NP cell medium containing 2% fetal bovine serum (FBS), 1% NP cell growth supplement, and 1% penicillin/streptomycin solution. Cells were seeded into T-25 flasks (Corning Life Sciences, NY) at a cell density of 5000 cells/cm 2 . Cultures were kept at 37 C in a 5% CO 2 -95% air atmosphere and medium was changed every three days until the culture was approximately 70% confluent, after which medium was changed every other day. When 90% confluence was reached, cells were subcultured with trypsin-EDTA (0.25% trypsin, 0.5 mmol/L EDTA). NP cells were used within the first five passages. To investigate the effect of TNF-a, different final concentrations (10-120 ng/mL) of TNF-a were added to NP cell medium after attachment of NP cells to flasks or plates for 24 h or 48 h.
CCK-8 analysis
NP cells were transferred to 96-well plates at a cell density of 4000 cells/well. Cells were treated with TNF-a (0, 20, 40, 80, 120 ng/mL) and cultured at 37 C in a 5% CO 2 -95% air atmosphere for 48 h. Cell proliferation was assessed using CCK-8 according to the manufacturer's protocol. For inhibitor treatment experiments, cells were pretreated with inhibitors for NF-kB (pyrrolidinedithiocarbamate ammonium, 100 mmol/L), p38 (SB203580, 10 mmol/L), Erk (U0126, 10 mmol/L) or JNK (SP60025, 10 mmol/L) for 20 min prior to TNF-a treatment (100 ng/mL).
Ki67 immunofluorescence staining
NP cells were seeded onto 12 mm glass coverslips. Cells were treated with TNF-a (0, 20, 40, 80, 120 ng/mL) and cultured at 37 C in a 5% CO 2 -95% air atmosphere for 48 h. Then, cells were washed with phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde for 25 min at room temperature. Cells were washed three times with PBS and permeabilized with 0.2% Triton X-100/PBS for 15 min. Nonspecific binding was blocked by incubating cells in 5% bovine serum albumin (BSA)/PBS for 60 min. Cells were incubated overnight at 4 C with rabbit polyclonal anti-Ki67 antibody (1:400 dilution) in 1% BSA/PBS. After thorough washing of the cells, the bound primary antibody was detected by incubating the cells for 2 h at room temperature in the dark with an Alexa Fluor 594 conjugated donkey anti-rabbit IgG. Nuclei were counterstained with 4'6-diamidino-2-phenylindole (DAPI) at 37 C for 2 min. Fluorescence was visualized using a laser scanning confocal microscope (FV2000, Olympus, Tokyo, Japan). Negative controls were prepared without primary antibody (anti-Ki67). The total numbers of nuclei (blue) and the number of Ki67-stained nuclei (pink) were counted. Proliferation was quantified by determining the percentage of Ki67 positive cells compared to the total number of cells counted.
Quantitative real-time RT-PCR
Gene expression of cyclin B1 was analyzed by real-time RT-PCR. Briefly, cells were treated with TNF-a (0, 120 ng/mL) and cultured at 37 C in a 5% CO 2 -95% air atmosphere for two days. After treatment, cells were harvested and washed with PBS. Total RNA was prepared, measured, and cDNA synthesis was performed. Specific primers were designed for the different target genes based on published gene sequences (NCBI Nucleotide database). PCR reactions were performed in a StepOnePlus real-time PCR system (Applied Biosystems) according to the manufacturer's instructions. Transcript levels were normalized using glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Melting curves are analyzed to verify the specificity of the RT-PCR reaction and the absence of primer dimer formation. Real-time PCR primer sequences are as follows: human cyclin B1 (F: 5' ACATGGTGCACTTTCCTCCT 3', R: 5' AGGTAATGTTGTAGAGTTGGTGTCC 3'), human GAPDH (F: 5' ATGGGGAAGGTGAAGGTCG 3', R: 5' TAAAAGCAGCCCTGGTGACC 3').
Cell cycle analysis
Cells were treated with TNF-a (0, 10, 100 ng/mL) and cultured at 37 C in a 5% CO 2 -95% air atmosphere for 24 h. Cells were harvested, washed with PBS, and centrifuged at 1000 r/min for 10 min, after which the supernatant was carefully aspirated. Five milliliters of cold 75% ethanol were added in a dropwise manner to the centrifuge tubes, which were then incubated at À20 C overnight. Cells were washed once with PBS and once with stain buffer, after which they were centrifuged for 10 min at 1500 r/min, and the supernatant was aspirated. Cells were resuspended in 0.5 mL of PI/RNase staining buffer, incubated for 15 min at room temperature, and analyzed on a flow cytometer (BD Biosciences) immediately thereafter. Data were analyzed using FlowJo software. Results are expressed as the percentage of cells in S phase in each group.
Apoptosis analysis
Cells were treated with TNF-a (0, 10, 100 ng/mL) and cultured at 37 C in a 5% CO 2 -95% air atmosphere for two days. Cell apoptosis analysis was performed using an Annexin V-FITC & PI apoptosis detection kit. Briefly, cells were harvested and washed with PBS. After centrifuging, cells were resuspended in 300 mL 1 Âbinding buffer and incubated with 5 mL Annexin V-FITC and 5 mL PI for 5 min at room temperature in the dark. Cells were analyzed on a flow cytometer. The results are expressed as the percentage of apoptotic cells in each group. 
Statistical analysis
Data are presented as mean AE standard error of mean (SEM). Differences between groups were analyzed by oneway analysis of variance (ANOVA) and Student's t-test (SPSS for Windows version 17.0, Chicago, IL). P < 0.05 was considered statistically significant. Significant differences compared with appropriate controls are denoted with asterisks: *P < 0.05; **P < 0.01; ***P < 0.001. All experiments were repeated at least three times independently.
Results
TNF-a induces proliferation of human NP cells
The effect of TNF-a on the proliferation of human NP cells was evaluated by CCK-8 analysis. As shown in Figure 1a , the proliferation of human NP cells was significantly stimulated by TNF-a in a dose-dependent manner over a dose range of 20-120 ng/mL. To further validate the role of TNFa on proliferation of human NP cells, we next carried out Ki67 immunofluorescence staining and cell cycle analysis. There was a trend towards a positive correlation between the percentage of Ki67 positive NP cells and the concentration of TNF-a, although this failed to reach statistical significance. Compared with control cells, treatment with TNF-a increased the percentage of Ki67 positive NP cells (Figure 1b and c) , indicating a positive effect of TNF-a on NP cell proliferation.
To further confirm the TNF-a induction of NP cell proliferation, we studied expression of cyclin B1 and cell cycle distribution in TNF-a-treated cells. As shown in Figure 2 , TNF-a treatment induced a significant increase in cyclin B1 mRNA levels. In addition, relative to untreated cells, treatment with 100 ng/mL TNF-a effected a significant increase in the S phase NP cell population (Figure 3) , again validating the stimulation by TNF-a of NP cell proliferation.
TNF-a inhibits apoptosis in human NP cells
We next determined the effect of TNF-a on NP cell apoptosis using an Annexin V-FITC & PI apoptosis detection kit. As shown in Figure 4 , relative to control cells, treatment with TNF-a at 10 and 100 ng/mL effected a significant dose-dependent decrease in the number of apoptotic NP cells.
TNF-a promotes proliferation of human NP cells by activating NF-iB and MAPK signaling
We next used selective inhibitors of major signaling pathways to identify the mechanism by which TNF-a induced NP cell proliferation. We found that NP cell proliferation induced by 100 ng/mL TNF-a was significantly inhibited by the NF-kB inhibitor pyrrolidinedithiocarbamate ammonium, the p38 inhibitor SB203580, and the JNK inhibitor SP60025, but not by the Erk inhibitor U0126 ( Figure 5 ).
TNF-a activates NF-iB and MAPK in human NP cells
To further validate the role of NF-kB, JNK, and p38 mitogen-activated protein kinase (MAPK) signaling in TNF-a induction of NP cell proliferation, we next evaluated the extent to which these signaling pathways were activated by treatment with TNF-a. As shown in Figure 6 , 100 ng/mL TNF-a rapidly induced p-JNK (<5 min treatment), and p-p65 and p-38 MAPK (<15 min treatment), after which levels of these proteins declined (1 h treatment). TNF-a had no effect on total cellular levels of p65, JNK, or p38 MAPK. These results confirm that TNF-a activates the p65, JNK, and p38 MAPK signaling pathways in NP cells.
Discussion
Our study demonstrates for the first time that acute exposure of TNF-a enhances survival of human NP cells by Figure 2 Effect of TNF-a on cyclin B1 expression in NP cells. Expression of cyclin B1 was studied using quantitative real-time RT-PCR. Treatment with TNFa (100 ng/mL) for two days resulted in a significant increase in cyclin B1 mRNA levels. n ¼ 3 Figure 3 Effect of TNF-a on cell cycle distribution of NP cells. Treatment with TNF-a (10 or 100 ng/mL) for 24 h increases the S phase population. n ¼ 3 promoting proliferation and inhibiting apoptosis. Moreover, TNF-a stimulation of NP cell proliferation is dependent upon the integrity of the NF-kB, JNK, and p38 signaling pathways. These results point to a proliferative role of TNF-a in IVD at the very beginning of TNF-a exposure.
TNF-a was initially identified as an inducer of necrosis in mouse solid tumors, 29 and was subsequently characterized as potent proinflammatory cytokine with important roles in many pathophysiological processes. TNF-a has multiple context specific effects on fundamental cellular processes, including induction of cell senescence, 30,31 apoptosis 32,33 as well as proliferation. 20, 22, 34 A variety of studies have pointed to a role for TNF-a in the pathogenesis of IVD herniation, degeneration, and sciatic pain. Elevated levels of TNF-a are present in herniated discs, 1 and in the serum of patients with chronic low back pain due to herniated disc. 35 Moreover, TNF-a expression in IVDs has been shown to be associated with the degree of disc degeneration, 3 and TNFa is known to play important roles in disc cell apoptosis, disc herniation, and nerve irritation. 36 Consistent with these observations, TNF-a has been shown to stimulate expression of catabolic MMPs, ADAMTS-4, and ADAMTS-5. 11, 37, 38 Despite this wealth of evidence implicating TNF-a in degenerative disc conditions, however, the effect of TNFa on human NP cells has to date been unclear.
Our results show that TNF-a promotes proliferation and suppresses apoptosis in NP cells. CCK-8 assay and Ki67 immunofluorescence analysis demonstrated that TNF-a effected proliferation of NP cells in a dose-dependent manner, observations that were supported by the increased expression of cyclin B1 and increased number of S phase cells after TNF-a treatment. A recent study showed that treatment of human NP cells with TNF-a for 24 h enhances Notch signaling, 39 which has in turn been shown to be a critical component of NP cell proliferation. 40 In contrast however, treatment of whole bovine disc culture with TNF-a for seven days resulted in the appearance of senescent NP cells. 10 These contrasting results may be attributed to the differing durations of TNF-a treatment, such that a brief exposure to TNF-a induces an acute inflammatory reaction and promotes NP cell proliferation, while a longer treatment time results in a subacute or chronic inflammatory reaction, ultimately effecting senescence in NP cells.
A number of studies have demonstrated that TNF-a alternately induces survival or apoptosis in a variety of cell types. [41] [42] [43] [44] [45] In this study, we found that TNF-a treatment for two days significantly reduced NP cell apoptosis in a dose-dependent manner. Together with the promotion by TNF-a of NP cell proliferation, these data indicate that NP cells may be involved in the promotion of tissue repair under acute inflammatory conditions. Increased levels of TNF-a in IVD results in induction of NP cell proliferation, subsequently leading to inflammatory hyperplasia. Given the scarcity and uneven availability of cellular nutrients and oxygen in degenerative discs, TNF-a induction of NP cell proliferation would be anticipated to occur only in locations with elevated levels of nutrients and oxygen, leading to the ; 10 mmol/L) blocked TNF-a-induced proliferation of NP cells, with the exception of Erk1/2 (U0126; 10 mmol/L) inhibition, which had no effect on the TNF-a-induced proliferation of NP cells. n ¼ 4 Figure 6 Effect of TNF-a on levels of activated NF-kB, JNK, and p38 in NP cells. Western analysis indicated that treatment of NP cells with TNF-a for less than 15 min induced phosphorylation of p65, JNK, and p38, with no appreciable effect on the overall cellular levels of p65, JNK, and p38 formation of NP cell clusters. The excessive proliferation of NP cells that would ensue would have the likely effect of further compromising the nutritional environment of the disc, and exacerbating disc degeneration.
Although recent evidence indicates that the NF-kB and MAPK signaling pathways are master regulators of inflammation and catabolism in IVD degeneration, 12, 14, 46 they also play critical roles in regulation of cell proliferation. 47, 48 Although the mechanism is unknown, several reports indicate that TNF-a induction of NP cell proliferation is mediated by NF-kB and MAPK signaling pathways. 39, 43, 45 NF-kB has been implicated in TNF-a enhancement of 17bestradiol-induced cell proliferation in estrogen-dependent breast tumor cells, 45 and in TNF-a induction of proliferation in mouse colon cancer cells. 43 Moreover, TNF-a induction of Notch pathway genes involved in regulation of cell proliferation occurs via NF-kB and MAPK signaling. 39 Here, we demonstrated that inhibitors of NF-kB, JNK, and p38 MAPK block TNF-a-stimulated NP cell proliferation, supporting the notion that the NF-kB, JNK, and p38 MAPK signaling pathways play key roles in the TNF-a-dependent cell proliferation. The fact, however, that inhibition of Erk1/ 2 had no effect on TNF-a stimulation of NP cell proliferation, indicates that distinct signal pathways are involved in TNF-a-induced cell proliferation in different cell types.
Although the relationship between TNF-a and intervertebral disk disease (IVDD) has been well characterized, the exact effect of TNF-a on NP cells has until now not been fully investigated. The current study has shown that a brief exposure of TNF-a promotes proliferation of human NP cells through NF-kB, JNK, and p38 MAPK, but not Erk1/ 2. Our findings suggest that after short-term exposure of TNF-a, NP cells are proliferative rather than senescent and necrotic.
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